Securities code: 688180 Securities abbreviation: Junshi Biosciences Announcement Number: Pro 2025-008

Shanghai Junshi Biomedical Technology Co., Ltd

2024 Annual Results Express Announcement

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

The main financial data of 2024 contained in this announcement are preliminary accounting data, which have not been audited by accounting firms, and the specific data are subject to the 2024 annual report of Shanghai Junshi Biomedical Technology Co., Ltd. (hereinafter referred to as the "Company"), and investors are reminded to pay attention to investment risks.

1. Main financial data and indicators for 2024

Unit: RMB 10,000 yuan

　　■

Note: 1. The beginning of the reporting period is the same as the end of the previous year as disclosed by law.

2. The above financial data and indicators are filled in with the consolidated statement data, but they are unaudited, and the final results are subject to the company's 2024 annual report.

2. Explanation of operating performance and financial situation

(1) The operating situation, financial situation and main factors affecting the operating performance in the reporting period:

During the reporting period, the company's operating income increased, mainly due to the increase in sales revenue of commercial drugs compared with the same period last year. As of the end of the reporting period, the company had toripalimab injection (trade name: Tuoyi?) ), adalimumab injection (trade name: Junmaikang?) ), deuterium hydrobromide deuterium remidevir tablets (trade name: Mindwei? ) and ongoresimab injection (trade name: Junshida?) Four commercialized drugs. Thanks to the improvement of the sales efficiency of the company's commercialization team, the number of approved indications for toripalimab and the indications included in the national medical insurance catalogue increased, and the sales of the company's core product toripalimab in the domestic market increased by more than 60% year-on-year during the reporting period.

As of the disclosure date of this announcement, toripalimab has been approved for marketing in the United States, the European Union, India, the United Kingdom, Jordan, Australia and other countries and regions, and the marketing authorization application in Singapore has been accepted. The Company and its partners will actively promote the marketing application and commercialization process of toripalimab in the cooperative regions, and actively explore the possibility of more indications being marketed in some regions.

With the improvement of the accessibility of approved products and indications after they are included in the National Medical Insurance Catalogue, the successive approval of more products and indications for marketing in the future, and the continuous commercialization expansion of the global market, the company's commercial competitiveness will continue to be improved.

In 2024, the company will actively implement the action plan of "improving quality and efficiency and emphasizing returns", continue to strengthen various cost control, reduce unit production costs, improve sales efficiency, and focus resources on more potential R&D projects. During the reporting period, the company's core pipeline has been efficiently advanced and has made a number of progresses, such as the new indication application of toripalimab for the first-line treatment of advanced triple-negative breast cancer, the first-line treatment of advanced renal cell carcinoma and the first-line treatment of extensive-stage small cell lung cancer was approved by the National Medical Products Administration (hereinafter referred to as the "NMPA"), and the new indication application for the first-line treatment of melanoma and the first-line treatment of advanced hepatocellular carcinoma in combination with bevacizumab was accepted by the NMPA; Ongoliximab injection was approved for marketing by the State Food and Drug Administration. The company is accelerating the R&D and marketing application of late-stage pipelines such as anti-tumor anti-BTLA monoclonal antibody tifcemalimab (code: TAB004/JS004) and anti-IL-17A monoclonal antibody (code: JS005), and continues to explore including PD-1/VEGF bispecific antibody (code: JS207), Claudin18.2 ADC drug (code: JS107), PI3K-α is an early-stage pipeline of oral small molecule inhibitors (code: JS105), CD20/CD3 bispecific antibodies (code: JS203), anti-DKK1 monoclonal antibody (code: JS015) and other products, and promotes more advantageous products and indications to enter the registration and clinical trial stage as soon as possible.

(2) The main reasons for the change of the main indicators:

1. During the reporting period, the company's operating income increased by 29.67% over the same period of last year, mainly due to the increase in sales revenue of commercial drugs compared with the same period last year. As of the end of the reporting period, the company had toripalimab injection (trade name: Tuoyi?) ), adalimumab injection (trade name: Junmaikang?) ), deuterium hydrobromide deuterium remidevir tablets (trade name: Mindwei? ) and ongoresimab injection (trade name: Junshida?) Four commercialized drugs. Thanks to the improvement of the sales efficiency of the company's commercialization team, the number of approved indications for toripalimab and the indications included in the national medical insurance catalogue increased, and the sales of the company's core product toripalimab in the domestic market increased by more than 60% year-on-year during the reporting period.

2. During the reporting period, the operating profit, total profit, net profit attributable to the owners of the parent company, net profit attributable to the owners of the parent company after deducting non-recurring gains and losses, basic earnings per share, and weighted average return on equity decreased compared with the same period last year, mainly due to the company's active implementation of the action plan of "improving quality and efficiency and emphasizing returns", continuously strengthening the control of various expenses, reducing unit production costs, improving sales efficiency, and focusing resources on more potential R&D projects.

3. Risk Warning

The company does not have any significant uncertainties that affect the accuracy of the content of this performance report.

The main financial data of 2024 contained in this announcement are preliminary accounting data, which have not been audited by accounting firms, and the specific data are subject to the company's 2024 annual report.

The announcement is hereby made.

Shanghai Junshi Biomedical Technology Co., Ltd

Board of Directors

February 28, 2025